In short
Mirabegron, also known by brand names like Betmiga, Myrbetriq, and Betanis, is a medication being studied in clinical trials for the treatment of overactive bladder (OAB) and related conditions. These trials aim to evaluate its effectiveness, safety, and how it works in the body across different patient groups, including adults and children. The research explores various aspects such as quality of life improvements, long-term effects, and comparisons with other treatments.
At a glance
- Drug Name
- Mirabegron (also known as Betmiga, Myrbetriq, Betanis, YM178)
- Primary Conditions Studied
- Overactive Bladder (OAB), Neurogenic Detrusor Overactivity (NDO), Urgency Incontinence
- Age Groups
- Adults and children (including studies on children as young as 6 months)
- Administration Methods
- Oral tablets, oral suspension, intravenous (IV) infusion
- Key Outcome Measures
- Quality of life, bladder capacity, urgency episodes, pharmacokinetics, safety profile
- Study Designs
- Randomized controlled trials, open-label studies, bioequivalence studies, long-term safety studies
- Duration of Studies
- Ranging from single-dose studies to long-term studies up to 52 weeks
What is Mirabegron?
Mirabegron is a medication primarily used to treat overactive bladder (OAB). It was developed by Astellas Pharma and approved by the United States Food and Drug Administration (FDA) in July 2012. Mirabegron belongs to a class of drugs called β3 adrenergic receptor agonists, which means it works by activating certain receptors in the bladder to help it function better.
What Conditions Does Mirabegron Treat?
Mirabegron is primarily used to treat the following conditions:
- Overactive Bladder (OAB): A condition characterized by sudden urges to urinate that are difficult to control, frequent urination, and sometimes involuntary loss of urine.
- Urgency Incontinence: A type of urinary incontinence where you suddenly feel the need to urinate and may leak urine before reaching the toilet.
- Neurogenic Detrusor Overactivity (NDO): A condition where the bladder contracts involuntarily due to nerve problems, often seen in patients with neurological disorders.
How Does Mirabegron Work?
Mirabegron works differently from other OAB medications. It activates β3 adrenergic receptors in the bladder muscle, which helps the bladder relax and increases its capacity to hold urine. This action can reduce the frequency of urination and the sudden urges to urinate that are common in OAB.
Brand Names and Forms
Mirabegron is marketed under several brand names worldwide:
- Myrbetriq
- Betmiga
- Betanis
- Bladogra
It is available in different forms, including:
- Extended-release tablets (usually 25 mg or 50 mg)
- Oral suspension (for children or adults who have difficulty swallowing tablets)
Effectiveness of Mirabegron
Clinical studies have shown that Mirabegron can be effective in improving symptoms of OAB. Researchers use various measures to assess its effectiveness, including:
- Overactive Bladder Questionnaire (OAB-q): This measures the patient's quality of life related to bladder symptoms.
- Patient Perception of Bladder Control (PPBC): This assesses how patients perceive their bladder control.
- Urinary Distress Inventory (UDI): This measures how bothered patients are by urinary symptoms.
These measures help doctors understand how well the medication is working for individual patients.
Potential Side Effects
Like all medications, Mirabegron can cause side effects. Common side effects may include:
- Increased blood pressure
- Urinary tract infections
- Headache
- Constipation
It's important to note that not everyone experiences side effects, and your doctor will monitor you closely while you're taking this medication.
Usage in Children
Mirabegron is also being studied for use in children with overactive bladder or neurogenic detrusor overactivity. A special oral suspension form has been developed for children who may have difficulty swallowing tablets. However, its use in children is still under investigation to determine the appropriate dosage and safety profile.
Combination Therapy
In some cases, Mirabegron may be used in combination with other medications to treat OAB, particularly in men who also have benign prostatic hyperplasia (enlarged prostate). For example, it may be combined with drugs called alpha-blockers like Tamsulosin. This combination therapy aims to address multiple aspects of urinary symptoms and may provide better symptom relief for some patients.